Alnylam Pharmaceuticals, Inc.
ALNYHealthcareNASDAQBiotechnology · Last scanned Sep 5, 2026
Scan Results
Daily timeframeAlnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. At a $35.61B market cap, Alnylam Pharmaceuticals, Inc. ranks as a large-cap company within healthcare. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1.
Market Cap
$35.61B
Beta
0.30
P/E (TTM)
46.36
P/E (Fwd)
21.14
EPS (TTM)
$5.74
EPS (Fwd)
$12.59
ROE
96.6%
ROA
12.3%
Cash
$3.31B
Total Debt
$2.99B
Free CF
$271.5M
52W Change
-41.9%
Annual Financials
Cash vs Debt
Where ALNY stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, ALNY finished 9.29% below its 150-day moving average ($294.78) and 17.22% below its 200-day moving average ($323.03). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ALNY overbought or oversold?
At the September 3, 2026 close, ALNY's RSI(14) was 74.4, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $3.31B in cash comfortably exceeding the $2.99B debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Annual free cash flow of $271.5M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of 96.6% points to exceptionally high capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Return on assets of 12.3% further supports the picture of efficient asset utilization. Revenue has grown from $1.04B (2022) to $3.71B (2025), reflecting a 258% increase over the period.
The relatively low beta of 0.30 suggests ALNY is a less volatile holding compared to the broader index. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Alnylam Pharmaceuticals, Inc.'s trajectory.